Oncolytics Biotech Inc. ONCY
Regular-session close
After hours · Nov 20, 7:07 PM ET
- YTD
- -59.76%
- 1 year
- -64.64%
5D +0.0206 (+5.57%)
- Market cap
- 47.66M
- EPS (ttm)
- -0.30
- Shares out
- 77.07M
- Forward P/E
- -3.02
- YTD return
- -59.76%
- 1-year return
- -64.64%
- 50-day average
- 1.04
- 200-day average
- 1.04
- Volume
- 1.11M
- Avg volume
- 1.16M
- Open
- 0.38
- Previous close
- 0.3906
- Day's range
- 0.34 – 0.3885
- 52-week range
- 0.33 – 1.30
- Beta
- 1.51
- Price target
- 4.85 (+1285.9%)
Key statistics
- Enterprise value
- 55.56M
- Price / book
- 2.45
- Free cash flow
- -15.77M
- Total cash
- 24.85M
- Total debt
- 1.12M
- Return on equity
- -138.22%
- Short % of float
- 3.89%
Fundamental scorecard
1 of 25 checks passed on ONCY’s reported financials
1of 25 checks passed
- Value 0 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 1 of 5
- Dividend No data
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.08 | -0.09 | -0.01 | -12.50% |
| Aug 1, 2024 | Jun 1, 2024 | -0.08 | -0.07 | +0.01 | +12.50% |
| May 9, 2024 | Mar 1, 2024 | -0.09 | -0.07 | +0.02 | +22.22% |
| Mar 7, 2024 | Dec 1, 2023 | -0.11 | -0.04 | +0.07 | +63.64% |
| Nov 3, 2023 | Sep 1, 2023 | -0.07 | -0.10 | -0.03 | -42.86% |
| Aug 14, 2023 | Jun 1, 2023 | -0.09 | -0.09 | 0.00 | 0.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 19, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 21, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 4, 2024 | Raymond James | init | — | Outperform |
| Mar 8, 2024 | HC Wainwright & Co. | main | Buy | Buy |
About Oncolytics Biotech Inc.
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- oncolyticsbiotech.com
News
HC Wainwright & Co. Reiterates Buy on Oncolytics Biotech, Maintains $5 Price Target
Oncolytics Biotech® Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI® (toripalimab-tpzi) in SCAC Oncolytics Biotech Announces New Translational Data From An Ongoing Study Showing Pelareorep’s Ability To Increase HPV-16-Specific T Cell Clones And Tumor-Infiltrating Lymphocyte Clones In Second-Line Or Later Squamous Cell Anal Cancer Patients; Immune Activation Levels More Than Doubled In Nearly All Patients After One Cycle Of Treatment; Substantial Increases In HPV-16-Specific T Cells And Tumor-Infiltrating Lymphocytes Observed When Pelareorep Is Combined With A Checkpoint Inhibitor
Oncolytics Biotech Announces Its Group 4 Of Phase 1/2 GOBLET Trial Of Pelareorep In Combination With Atezolizumab Failed to Reach Median Overall Survival
Oncolytics Biotech To Present Trail-In-Progress Abstract, E-Poster For Its REO 033 Trial At European Society For Medical Oncology
Your note
Sign in to keep a note on ONCY — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| International Assets Investment Management, LLC | 0.26% | 198,400 | 179.71K | Jun 29, 2024 |
| Seeds Investor LLC | 0.25% | 189,941 | 172.05K | Sep 29, 2024 |
| Goldman Sachs Group Inc | 0.11% | 84,998 | 76.99K | Sep 29, 2024 |
| Royal Bank of Canada | 0.10% | 74,546 | 67.52K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.10% | 79,249 | 71.78K | Sep 29, 2024 |
| Commonwealth Equity Services, LLC | 0.08% | 61,114 | 55.36K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.05% | 41,942 | 37.99K | Oct 30, 2024 |
